Ruigang Cai

Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Fei Ma, Qiao Li, Shanshan Chen et al. · Journal of Clinical Oncology · 2017 · 234 citations

Medicine, Oncology, Pharmacology +17

In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China

Yiqun Li, Nilupai Abudureheiyimu, Hongnan Mo et al. · Frontiers in Oncology · 2022 · 119 citations · Full text

Medicine, Oncology, Pathology +17

The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first‐line chemotherapy of HER2‐negative metastatic breast cancer

Xiuwen Guan, Fei Ma, Chunxiao Li et al. · Cancer Communications · 2019 · 114 citations · Full text

Medicine, Cancer Biology, Oncology +17

RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies.

Jiayu Wang, Yunjiang Liu, Qingyuan Zhang et al. · Journal of Clinical Oncology · 2021 · 102 citations

Medicine, Oncology, Pharmacology +15

Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial

Pin Zhang, Yi Yin, Hongnan Mo et al. · Oncotarget · 2016 · 96 citations · Full text

Medicine, Oncology, Pharmacology +17